Researchers have developed a new drug that could help prolong the lives of people with glioblastoma brain cancer.
Researchers have identified a specific group of circulating tumor cells in the blood stream of patients with breast cancer brain metastases. The finding is helping researchers to develop a new blood test to identify breast cancer patients at risk of developing brain metastasis.
Researchers have developed a new method of reducing the time it takes to grow mini brain models in the lab. This may accelerate research into diseases and injury that affect the nervous system.
A major finding from researchers at Houston Methodist reveals a significant number of people diagnosed with schizophrenia or bipolar disorder may actually have a treatable immune system disorder. The condition causes NMDA receptors to stop functioning properly and can result in symptoms commonly associated with neuropsychiatric disorders.
A compound used to treat leukemia shows promise in preventing breast cancer cells from metastasizing in the brain.
A new immunotherapy treatment for ALS patients is not only safe, but can also help slow the progression of the disease, researchers report.
Binge-watching TV shows can create an unhealthy environment for the brain due to social isolation, sleep deprivation and unhealthy eating habits.
OCIAD1, a protein commonly associated with ovarian cancer, contributes to neurodegeneration in Alzheimer's disease by impairing mitochondrial function, leading to synaptic damage and neural vulnerability.
On Saturday, the FDA approved Houston Methodist to conduct transfused plasma therapy for the treatment of COVID-19. The plasma will be donated from recovered COVID-19 patients and transfused into those critically ill with the virus. Researchers have already begun recruiting donors in the Houston area who have recovered from coronavirus. The first donor was a patient in the Houston Metropolitan area who has been in good health for two weeks following COVID-19 infection.
Researchers conducting a clinical trial of Remdesivir to treat coronavirus report the drug appears to be promising. The drug, initially designed to treat Ebola, is well tolerated, and patients treated with the drug are showing signs of recovery. Early indications suggest Remdesivir could stave off the need for intubating patients suffering from COVID-19.
MP-Pt(IV), a second generation prodrug appears to have curative properties against glioblastoma when coupled with chemotherapy in mouse models.
Researchers have identified acute transverse myelitis (ATM) in a number of COVID-19 patients. ATM, which is marked by inflammation of the spinal cord, is a rare neurological disorder that can lead to spinal cord lesions, paralysis, and bowel dysfunction.
